Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 4/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 4/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17166114 | 0.93 | PDPK1 (0.55) | PDPK1PTGS2ALDH1A1HPGDCYP1A2 | |
| SCHEMBL12054881 | 0.88 | PDPK1 (0.75) | PDPK1PTGS2ALDH1A1HPGDCYP1A2 | |
| SCHEMBL16196163 | 0.87 | CA9 (0.59) | PDPK1PTGS2ADORA3ADORA2AADORA2B | |
| SCHEMBL16195916 | 0.87 | PDPK1 (0.56) | PDPK1PTGS2ALDH1A1ADORA3ADORA2A | |
| SCHEMBL16196304 | 0.86 | PDPK1 (0.80) | PDPK1PTGS2 | |
| SCHEMBL15000396 | 0.86 | PDPK1 (0.55) | PDPK1PTGS2ALDH1A1HPGDCYP1A2 | |
| SCHEMBL14825410 | 0.85 | PDPK1 (0.62) | PDPK1PTGS2ALDH1A1HPGDCYP1A2 | |
| SCHEMBL16196246 | 0.83 | CA9 (0.66) | PDPK1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL2602397 | 0.81 | PDPK1 (0.62) | PDPK1PTGS2ALDH1A1HPGDCA9 | |
| SCHEMBL16196243 | 0.80 | PDPK1 (0.67) | PDPK1PTGS2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156790-B2 | Anticancer P21-activated kinase inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140323538-A1 | ANTICANCER P21-ACTIVATED KINASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323538-A1 | ANTICANCER P21-ACTIVATED KINASE INHIBITORS | CDKN1A, CDK2, CDK3 | PDPK1 286/4885PTGS2 1073/4885ALDH1A1 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.